Company intelligence / Profile preview

Aldena Therapeutics

Boston, Massachusetts, United Statesaldenatherapeutics.com ↗

Ownership: Private
Employees: ~5
Development stage: Preclinical

Overview

ALD-102, their lead product, is an siRNA-based investigational injectable treatment for inflammatory dermatological conditions currently in preclinical trials. The company is initiating the IND-enabling GLP nonclinical program for its lead projects.

Therapeutic areas: Dermatology
Modalities: siRNA-based therapies
Industry: Biotech

Partnerships

PCI Pharma Services (CDMO partner)EMPA (Swiss Federal Laboratories for Materials Science & Technology) under an Innosuisse grant

Beyond the preview

Go deeper on Aldena Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aldena Therapeutics.

Explore the full profile